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Introduction Migraine
Migraine is an idiopathic neurological disorder, which is characterised by spontaneous, recurrent headache attacks worsening the quality of life followed by symptom free intervals.
Its prevalence is very high, about 12% causing immense direct and indirect economic deficit.
Several theories have been put forward regarding the pathophysiology of migraine, but none of them can explain the full spectrum of the disorder. One of the common points in these different theories of migraine is the activation of the trigeminal system -responsible for most of the pain processing on the head -during the attack. The first-order trigeminal neurones contain numerous neurotransmitters such as glutamate and calcitonin gene-related peptide (CGRP), which are released during the activation. Consequently, enhanced CGRP level was measured in external jugular vein during the migraine attack, which contributes to the peripheral plasma extravasation and the neurogenic inflammation in the dura mater. The released inflammatory substances rapidly sensitize the trigeminal first-order neurones resulting in a throbbing head pain.
The primary nociceptors activate the second-order neurones in the spinal trigeminal nucleus pars caudalis (TNC) located in the medullary part of the brain stem blending into the substantia gelatinosa of the first two cervical spinal segments releasing mainly glutamate, which acts on its own ionotropic and metabotropic receptors located in the trigeminal system.
In response to activation, the expression of c-Fos transcription factor increases in the neurones, which is usually used as a marker of neuronal activation induced by noxious stimulation. Continuous excitation induces plastic and long-term changes in the second-order neurones resulting in central sensitization, which manifests clinically in cutaneous allodynia of scalp and face and worsens the efficacy of acute attack treatment with triptans. In these plastic changes, calcium/calmodulin-dependent protein kinase II alpha (CaMKIIα) plays an important role.
Since the exact pathomechanism of migraine is unknown and the current preventive and attack therapies are only partially effective and often poorly tolerated, scientific research is crucial in this field. Using animal experimental models, we can have better insight of the underlying mechanisms and a possibility to develop new drugs to treat the disorder. To summarize, numerous experimental results in animals confirm that NTG is able to activate and sensitize the trigeminal system -phenomena also observed during migraine attacks -making NTG administration an appropriate animal experimental model of migraine headache.
Nitroglycerin model of migraine headache
Kynurenines
The kynurenine pathway is an endogenous metabolic route, which is responsible for the 95% of tryptophan metabolism and many of its metabolites have neuroactive properties. Lkynurenine (L-KYN) itself is not a neuroactive compound, but it is the precursor of kynurenic acid, which is the main neuroprotective end product of this pathway probably due to various receptorial actions, like N-methyl-D-asparate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and α7-nicotinic acetylcholine (α7-nACh) receptor antagonism and G-protein-coupled receptor-35 (GPR-35) agonism. Changes in its concentration in pathological circumstances were described suggesting its role in pathomechanism of various neurological disorders. Furthermore, emerging evidence support that kynurenic acid can be crucial in nociception too. Based on these observations, kynurenic acid could provide a therapeutic option in many neurological diseases especially in migraine.
Unfortunately, it has only a very limited ability to cross the blood-brain barrier, therefore administration of L-KYN can be used in various experimental settings. Having a good bloodbrain barrier penetrance, L-KYN causes a dose-dependent increase in the level of kynurenic acid in the central nervous system, which can be amplified by a co-administration with probenecid (PROB). Furthermore, recent experimental results raise the possibility that application of various kynurenic acid derivatives with a presumed improved central nervous 7 system action and a retained pharmacological effect can be appropriate providing a promising therapeutic option instead of kynurenic acid.
Aims
The aims of our studies were to 
Materials and Methods
Animals, drugs and drug administration
The procedures followed the international and European guidelines ( 
Placebo of NTG.
For Western blotting, the animals received i.p. physiological saline in the control group and i.p. KYNAa2 (1 mmol/kg bw) in the second group followed by i.p. NTG (10 mg/kg bw) or i.p. Placebo one hour after the pre-treatment.
For the Open Field Test, the animals received i.p. physiological saline in the control group and i.p. 1 mmol/kg bw KYNAa2 in the second group followed by i.p. NTG (10 mg/kg bw) or i.p. Placebo one hour after the pre-treatment.
Kynurenic acid detection with HPLC
At determined time points (60 minutes in the control and L-KYN-PROB groups and 60 and 300 minutes in the KYNAa2 group) following the i.p. injection, the C1-C2 segments were removed. After sample preparation, the kynurenic acid content was measured with fluorescent detector. The retention time of kynurenic acid was about 6 minutes.
Immunohistochemistry
Four hours after treatment with Placebo or NTG, the C1-C2 segments were removed and processed for CGRP, c-Fos, nNOS and CaMKIIα immunohistochemistry. In laminae I and II of C1-C2, the area covered by CGRP-IR fibres was measured and number of c-Fos-, nNOSand CaMKIIα-IR cells were counted.
Western blotting
Four hours after the NTG or Placebo injections, the dorsal horn of C1-C2 segment was removed. After sample preparation, protein separation and transfer, the CGRP, nNOS and β-actin protein bands were indentified and their densities were measured.
Open Field Test
The rats were tested three hours and forty minutes after the NTG or Placebo injections in the Open Field box for 15 minutes and ambulation time, ambulation distance, local time and the number of rearings were registered and evaluated.
Results
Kynurenic acid detection with HPLC
The HPLC measurements of kynurenic acid concentration clearly indicated a robust, statistically significant increase in kynurenic acid level in the C1-C2 one hour after administration of L-KYN combined with PROB as compared with control group (p<0.001).
Similarly, kynurenic acid level in the C1-C2 showed a significant (p<0.05), more than twofold increase 60 minutes after 1 mmol/kg bw KYNAa2 administration compared to vehicle treated samples, while the concentration of kynurenic acid decreased to baseline at 300 minutes.
Immunohistochemistry
The transverse sections of the C1-C2 demonstrated abundant CGRP-positive fibres, and cFos-, nNOS-and CaMKIIα-IR neurones in the superficial layers (laminae I-II) of the dorsal horn. The area covered by IR fibres and the number of IR cells did not differ significantly between sections located at the various levels along the rostrocaudal axis or between the right and left dorsal horns of the cervical segments.
In the control group, significantly reduced CGRP staining and significantly increased c-Fos, nNOS and CaMKIIα immunoreactivity can be observed on the C1-C2 sections in I-II laminae after NTG treatment compared to Placebo treated rats (p<0.01, p<0.001).
Both L-KYN-PROB and KYNAa1 pre-treatment successfully attenuated the decrease in CGRP and increase in CaMKIIα immunopositivity (p<0.01, p<0.001). The pre-treatment with KYNAa2 affected dose-dependently the NTG-induced changes in the immunoreactivity of all studied markers. The administration of KYNAa2 in a dosage of 0.1 mmol/kg bw did not influence any of the alterations caused by NTG, whereas the pre-treatment with higher dosages of KYNAa2 (0.5 and 1 mmol/kg bw) was able to significantly reduce the effects of NTG on the CGRP-, c-Fos-, nNOS-and CaMKIIα-related changes in the C1-C2 (p<0.05, p<0.01, p<0.001).
Western blotting
Western blotting analysis of the C1-C2 region confirmed the results obtained by CGRP and nNOS immunohistochemistry. Densitometric analyses confirmed that the CGRP bands were significantly decreased (p<0.05) and nNOS bands were significantly enhanced (p<0.001) in dorsal horns of C1-C2 segments after NTG administration as compared with the Placebotreated animals. This effect of NTG on CGRP and nNOS was attenuated by pre-treatment with 1 mmol/kg bw KYNAa2.
Open Field Test
Treatment with NTG significantly decreased the ambulation distance of the animals compared to Placebo-treated rats (p<0.05). Pre-treatment with 1 mmol/kg bw KYNAa2 attenuated this difference, but a tendency for a lower basic ambulation distance was observed.
There were no significant changes in ambulation time, local time or in the number of rearings between the subgroups.
Discussion Kynurenic acid concentrations in the C1-C2
The HPLC data obtained after L-KYN-PROB show a robust increase of kynurenic acid concentration in the C1-C2, which corresponds to previous findings and supported by other studies. Kynurenic acid has a poor blood-brain barrier penetrance, but administration of its precursor, L-KYN increases kynurenic acid concentration in the central nervous system dosedependently. In experimental conditions, this effect of L-KYN can be enhanced with the coadministration of PROB by blocking the excretion of kynurenic acid, because it is a known inhibitor of organic acid transporters, which are involved in the transport of kynurenic acid from brain through the blood-brain barrier. Using kynurenic acid derivatives with a presumed better blood-brain barrier penetrance is an alternative option to increase kynurenic acid concentration or mimic its effect. After systemic administration KYNAa2, we witnessed a significant increase in the level of kynurenic acid in the C1-C2, suggesting that KYNAa2 is transformed at least partially to kynurenic acid. Similarly, transformation of KYNAa1 to kynurenic acid has been described after i.p. administration in mice serum, besides a robust increase of KYNAa1 level. Thus, central nervous effects of kynurenic acid derivatives might be related both to their direct action and to indirect influence via forming kynurenic acid.
Activation of primary trigeminal neurones
CGRP is an essential transmitter in the primary nociceptors and several lines of evidence proves its importance in migraine pathogenesis. Systemic NTG was able to reduce the CGRP content of the C1-C2, which is in line with earlier experiments. NO released from NTG 
Activation of second-order trigeminal neurones
The NO-induced c-Fos expression observed at the level of the C1-C2 reflects an activation of the second-order trigeminal nerve cells, which was already described in earlier studies and appears to be selective to the trigeminal system. NO might activate primary sensory fibres in the trigeminal system, since the depletion of neurotransmitter by capsaicin from these 
Conclusions
Kynurenic acid and its derivatives mitigated the NTG-induced trigeminal activation at the level of first-and second-order neurones and abolished changes related to the central sensitization process at the level of the C1-C2, where most of the second order trigeminal nociceptors are located. Since these events have a particular importance in the pathomechanism of headaches, kynurenic acid and its derivatives might have a potential role in the treatment of cephalalgias.
